Clinical Trial

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Study acronym: MIGHT
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use highly mismatched unrelated HLA mismatched donors. Ultimately, an unrelated human leukocyte antigen (HLA) mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of this group of patients and truly enter the era of "everyone has a donor" for allo HSCT.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-30.
Trial Details
NCT Number NCT06809712
Lead Sponsor He Huang
Conditions Hematologic Disease
Enrollment 29 participants
Start Date 2022-08-04
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09